Medical Advocates
HAART/ART
 
Viral Dynamics
               
General Reports
 Viral Rebound          









 






 
HAART Main Page Main New/Newsworthy  Home Page      
Last Update:  March 26, 2012  
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
 

     Journal Papers, Abstracts, and Commentaries        

 
Improved Virological Outcome in White Patients Infected With HIV-1 Non-B Subtypes Compared to Subtype B.
Scherrer AU, Ledergerber B, von Wyl V, et al
Clin Infect Dis. 2011 Oct 13.
 Abstract

Food Insecurity is Associated with Poor Virologic Response among HIV-Infected Patients
Receiving Antiretroviral Medications.
Wang EA, McGinnis KA, Fiellin DA, et al
J Gen Intern Med. 2011 May 15.
 Abstract

Virologic and immunologic response to HAART, by age and regimen class.
Althoff KN, Justice AC, Gange SJ, et al
AIDS. 2010 Sep 8.
 Abstract

The Effect of HAART on HIV RNA Trajectory Among Treatment-naïve Men and Women:
A Segmental Bernoulli/Lognormal Random Effects Model With Left Censoring.
Chu H, Gange SJ, Li X,  et al  
Epidemiology. 2010 Apr 7.
Abstract

Treatment response in acute/early infection versus advanced AIDS: equivalent first and second
phases of HIV RNA decline.
Kilby JM, Lee HY, Hazelwood JD, et al
AIDS. 2008 May 11;22(8):957-62.
 Abstract
 
Psychiatric Illness and Virologic Response in Patients Initiating Highly Active Antiretroviral
Therapy.
Pence BW, Miller WC, Gaynes BN, Eron JJ Jr.
J Acquir Immune Defic Syndr. 2006 Nov 30;
  Abstract

Treatment response in acute/early infection versus advanced AIDS: equivalent first and second
phases of HIV RNA decline.
Kilby JM, Lee HY, Hazelwood JD, et al
AIDS. 2008 May 11;22(8):957-62.
 Abstract
 
Rate of Viral Evolution and Risk of Losing Future Drug Options in Heavily Pretreated,
HIV-Infected Patients Who Continue to Receive a Stable, Partially Suppressive Treatment
Regimen.
Hatano H, Hunt P, Weidler J, et al 
Clin Infect Dis. 2006 Nov 15;43(10):1329-36.
Abstract
 
Discordant immunological and virological responses to antiretroviral therapy.
Schechter M, Tuboi SH.
Antimicrob Chemother. 2006 Jul 19;
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Regional Changes Over Time in Initial Virologic Response Rates to Combination Antiretroviral
Therapy Across Europe.
Bannister WP, Kirk O, Gatell JM, et al 
J Acquir Immune Defic Syndr. 2006 Jun;42(2):229-237.
 Abstract
 
Factors Associated with Poor Immunologic Response to Virologic Suppression by Highly
Active Antiretroviral Therapy in HIV-Infected Women.
Vaamonde CM, Hoover DR, Anastos K, et al
 AIDS Res Hum Retroviruses. 2006 Mar;22(3):222-31.
 Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
FULL-TEXT ARTICLE
 Viral Load Responses to HAART is an Independent Predictor of a New AIDS Event in Late Stage
HIV Infected Patients: Prospective Cohort Study.
Kazanjian P, Amin K, Brown M, Wei W.
J Transl Med. 2005 Oct 31;3(1):40 [
 PDF Paper
 
An improvement in virologic response to highly active antiretroviral therapy in clinical practice from
1996 through 2002.
Moore RD, Keruly JC, Gebo KA, Lucas GM.
J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):195-8.
 Abstract
 
Time to Virological Failure of 3 Classes of Antiretrovirals after Initiation of Highly Active
Antiretroviral Therapy: Results from the EuroSIDA Study Group.
 Mocroft A, Ledergerber B, Viard JP, et  al.
 J Infect Dis. 2004 Dec 1;190(11):1947-1956.
 Abstract

Long-Term CD4+ T-Cell Response to Highly Active Antiretroviral Therapy According to
Baseline  CD4+ T-Cell Count.
Garcia F, De Lazzari E, Plana M, et al  J
Acquir Immune Defic Syndr. 2004 Jun 1;36(2):702-713.
 Abstract

Long-term virological response to multiple sequential regimens of highly active
antiretroviral therapy for HIV infection.
Kaufmann GR, Khanna N, Weber R, et al 
Antivir Ther. 2004 Apr;9(2):263-74.
Abstract

CD4 T cell recovery is slower in patients experiencing viral load rebounds during
HAART.
 Scott-Algara D, Aboulker JP, Durier C, et al.
Clin Exp Immunol 2001 Nov;126(2):295-303
 Abstract
 
  HIV viral load response to antiretroviral therapy according to the baseline CD4
cell count and viral load.
Phillips AN, Staszewski S, Weber R, et al
JAMA. 2001 Nov 28;286(20):2560-7.
Abstract

     Conference Reports, Abstracts, and Posters

 
Using the yearly proportion of patients with undetectable viral load - a WHO indicator of HAART
effectiveness - in a middle-income country
S. Tuboi, A. Pacheco, S. May, et al
 (5th IAS Conference)
 Abstract

POSTER
Population Structure Analysis of HIV-I in Plasma and Integrated Provirus in Resting CD4+ T Cells Suggests
a Novel Source May Be the Dominant Contributor to Residual Viremia in Patients on HAART
T Brennan, J Woods, A Sedaghat , et al
(16 CROI)
 PDF Poster     Abstract
 

POSTER
 Intrathecal Immune Activation and Viral Changes in HIV-infected Naïve Patients with Advanced Disease after
Short-term HAART Introduction
M Airoldi, E Suard, A Soria, et al
 (16 CROI)
 PDF Poster     Abstract
 
POSTER
 Evidence of Persistent Low-level Viremia in Long-term HAART-suppressed Individuals
H Hatano, E Delwart, P Norris, et al
(16 CROI)
PDF Poster     Abstract
 
POSTER
 Age-specific CD4 Percentage and Weight/Growth Curves to Predict Survival and Virological Response
to HAART
M Yotebieng, H Moultrie, A Vanrie,  T Meyers
(16 CROI)
 PDF Poster     Abstract
 
Broad Inter-individual Variability in CD4+ Gain, Relative Proportion of Effector Memory T and Naive T
Subsets and Immune Activation in Patients with Viral Suppression on HAART
E Lazaro, L Wittkop, P Duffau, et al
 (16 CROI)
 Abstract
 
POWERPOINT POSTER PRESENTATION
 Virologic response to HAART among incarcerated HIV+ individuals
D Wohl 
(XVII International AIDS Conference)
 Poster Presentation
 
Treatment History but not Previous Genotype Improves the Accuracy of Predicting Virologic
Response to HIV Therapy
B. LARDER, D. WANG, A. REVELL ,  et al
 (46 ICAAC)  
 Abstract

Durability of HAART Regimens over Time
 (41 ICAAC)  
 Abstract

Viral Rebound
 

     Journal Papers, Abstracts, and Commentaries

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1
patients: a prospective cohort study. Swiss HIV Cohort Study.
 Ledergerber B, Egger M, Opravil M, et al.
Lancet. 1999 Mar 13;353(9156):863-8.
 Abstract
Magnitude of Virologic Blips Is Associated With a Higher Risk for Virologic Rebound in HIV-Infected
Individuals: A Recurrent Events Analysis.
Grennan JT, Loutfy MR, Su D,  et al
J Infect Dis. 2012 Apr;205(8):1230-1238
 Abstract

Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving
Highly Active Antiretroviral Therapy.
Doyle T, Smith C, Vitiello P, et al
 Clin Infect Dis. 2012 Jan 11.
 Abstract

Virological rebound after suppression on highly active antiretroviral therapy.
Mocroft A, Ruiz L, Reiss P
 AIDS. 2003 Aug 15;17(12):1741-1751.
Abstract
 
  Consecutive rebounds in plasma viral load are associated with virological failure at
52 weeks among HIV-infected patients.
 Raboud JM, Rae S, Woods R, et al
 AIDS. 2002 Aug 16;16(12):1627-32.
Abstract
 
  Raised viral load in patients with viral suppression on highly active antiretroviral therapy:
transient increase or treatment failure?
 Moore AL, Youle M, Lipman M, et al.
AIDS. 2002 Mar 8;16(4):615-8.
Abstract

HAART Main Page Main New/Newsworthy  Home Page      

HAART/ART Viral Dynamics